Expression of C-kit and Platelet-Derived Growth Factor Receptors in Ovarian Granulosa Cell Tumors

Abstract

Objective. This study aimed at evaluating the expression of tyrosine kinase receptors c-kit, (platelet-derived growth factor receptor-α (PDGFR-α), and PDGFR-β in ovarian granulosa cell tumors (GCTs). Study design. Primary ovarian GCT specimens were obtained for immunohistochemical staining.The expressions of c-kit, PDGFR-α, and PDGFR-β were analyzed and scored by a semiquantitative (SQ) method. Normal ovarian tissue from the same patients' specimens served as internal controls. Results. A total of 21 specimens were available for evaluation. C-kit was expressed in only 2 samples, whereas both PDGFR-α and PDGFR-β stained positive in 100% of tumors. PDGFR targets demonstrated strong positive expression in intensity and amount of tissue stained. Normal ovarian tissue demonstrated complete absence of staining for all 3 antibodies evaluated. Conclusions. The data demonstrated significant expression of PDGFR targets of imatinib mesylate in GCTs, whereas normal ovarian tissues had a complete absence of staining.This expression profile provides the rationale to investigate the role of imatinib mesylate in PDGFR-positive GCTs.

Keywords

Granulosa cell tumors c-kit platelet-derived growth factor imatinib mesylate.

Get full access to this article

View all access options for this article.

References

Hirota S. , Isozaki K. , Moriyama Y. , et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.

Tsujimura T. , Hashimoto K. , Kitayama H. , et al. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood. 1999;93:1319-1329.

Morin MJ From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and antiangiogenic agents. Oncogene . 2000;19:6574-6583.

Manning G. , Whyte DB , Martinez R. , Hunter T. , Sudarsanam S. The protein kinase complement of the human genome. Science . 2002;298:1912-1934.

Verweij J. , Judson I. , van Oosterom A. STI571: a magic bullet? Eur J Cancer. 2001 ;37:1816-1819.

Arber DA , Tamayo R. , Weiss LM Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol . 1998;29:498-504.

Henriksen R. , Funa K. , Wilander E. , Bäckström T. , Ridderheim M. , Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms . Cancer Res. 1993;53:4550-4554.

Matei D. , Graeber TG , Baldwin RL , Karlan BY , Rao J. , Chang DD Gene expression in epithelial ovarian carcinoma. Oncogene . 2002;21:6289-6298.

Schmandt RE , Broaddus R. , Lu KH , et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium . Cancer. 2003;98:758-764.

10.

Versnel MA , Haarbrink M. , Langerak AW , et al. Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet. 1994;73:60-64.

11.

Wilczynski SP , Chen YY , Chen W. , Howell SB , Shivley JE , Alberts DS Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol. 2005;36:242-249.

12.

Manne U. , Myers RB , Moron C. , et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer. 1997;74:346-358.

13.

Gershenson DM , Morris M. , Burke TW , Lavenback C. , Matthews CM , Wharton JT Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin . Obstet Gynecol. 1996;87:527-531.

14.

Homesley HD , Bundy BN , Hurteau JA , Roth LM Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;72:131-137.

15.

Lauszus FF , Petersen AC , Greisen J. , Jakobsen A. Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease. Gynecol Oncol. 2001;81:456-460.

16.

Leibl S. , Bodo K. , Gogg-Kammerer M. , et al. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: an immunohistochemical study. Gynecol Oncol . 2006; 101:18-23.

17.

Carvalho I. , Milanezi F. , Martins A. , Reis RM , Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression . Breast Cancer Res. 2005;7:R788-R795.

18.

Hwang RF , Yokoi K. , Bucana CD , et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res. 2003;9:6534-6544.

19.

Basciani S. , Brama M. , Mariani S. , et al. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity . Cancer Res. 2005;65:1897-1903.

20.

Beppu K. , Jaboine J. , Merchant MS , Mackall CL , Thiele CJ Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst. 2004;96:46-55.

21.

Kilic T. , Alberta JA , Zdunek PR , et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60:5143-5150.

22.

Krystal GW , Honsawek S. , Litz J. , Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000;6:3319-3326.

23.

Merchant MS , Woo CW , Mackall CL , Thiele CJ Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity . J Natl Cancer Inst. 2002;94:1673-1679.

24.

Sjoblom T. , Shimizu A. , O'Brien KP , et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001;61:5778-5783.

25.

Chu S. , Alexiadis M. , Fuller PJ Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecol Oncol. 2008;108:182-190.

26.

Tonary AM , Macdonald EA , Faught W. , Senterman MK , Venderhyden BC Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis . Int J Cancer. 2000; 89:242-250.

27.

Inoue M. , Kyo S. , Fujita M. , Enomoto T. , Kondoh G. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994;54:3049-3053.

28.

Parrott JA , Kim G. , Skinner MK Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod . 2000;62:1600-1609.

29.

Parrott JA , Mosher R. , Kim G. , Skinner MK Autocrine interactions of keratinocyte growth factor, hepatocyte growth factor, and kit-ligand in the regulation of normal ovarian surface epithelial cells . Endocrinology. 2000;141:2532-2539.